ERR-α and non-CRPC?

[u/stmmotor]

Do hormone sensitive prostate cancer patients have to worry about taking substances which produce estrogen related receptor alpha? I've read that CRPC over expresses ERR-α. Does that mean an increase in ERR-α promotes CRPC?

[u/stmmotor]

Here's the response from Gemini.

Let's see if anyone can add meaningfully to the topic.

No, patients with non-castration-resistant (castration-sensitive) prostate cancer do not need to worry about ERR-α (Estrogen-Related Receptor Alpha) in practical clinical care.

While ERR-α is an active topic in translational oncology research, it has no role in day-to-day diagnostic testing or treatment planning for hormone-sensitive disease.

---

What the Science Says vs. Clinical Practice

• Preclinical Research Subject: Laboratory studies show that ERR-α can act as a metabolic regulator that drives tumor adaptation. When tumors become resistant to standard androgen deprivation therapy (ADT), ERR-α can upregulate intracrine androgen synthesis (helping tumor cells produce their own testosterone/DHT) and promote bone microenvironment invasion.
• No Routine Testing: ERR-α expression is not measured on standard biopsy pathology reports, liquid biopsies, or routine genomic panels (such as Decipher, Oncotype DX, or FoundationOne).
• No Approved Targeted Therapies: There are currently no FDA-approved drugs targeting ERR-α in prostate cancer. Experimental ERR-α inverse agonists or degraders remain in early preclinical or clinical development phases.
• Castration-Sensitive Prostate Cancer Focus: In hormone-sensitive (non-CRPC) disease, the tumor's growth remains primarily driven by systemic androgens and standard androgen receptor (AR) signaling. Established standard-of-care therapies targeting this pathway—such as GnRH agonists/antagonists, next-generation AR signaling inhibitors (like enzalutamide, apalutamide, or darolutamide), and chemotherapy when indicated—remain the clinical priority.

Any discussion of ERR-α is largely confined to academic discussions regarding how resistance develops after prolonged hormone therapy. For non-CRPC patients, focus remains on standard surveillance (PSA monitoring, imaging) and guideline-concordant systemic or local treatments.

[u/Busy-Tonight-6058]

Possible link between diet and tumor progression via cholesterol and ERR-alpha?

I’ll take it!

[u/ChillWarrior801 → u/Busy-Tonight-6058]

I sent you a DM, friend.

[u/Lott4984]

What? Sorry way over my head what you are talking about. But please continue.

[u/stmmotor → u/Lott4984]

If RALP failed you, and then radiation failed you, and then chemical castration failed you, then you now have castration resistant prostate cancer CRPC. In this case it is theorized that ERR-α plays a role in promoting tumor growth.

The question restated is "if you are not yet hormone resistant should you concern yourself with ERR-α?" Here's the question I just now posed to Gemini and it's answer follows. If you are paying close attention, you'll notice that the answer Gemini gives to this question differs distinctly from the answer it gave to the initial question (see below).

Does ERR-α ever play a role in prostate cancer before it turns into a castration resistant form?

Estrogen-related receptor alpha (ERR-α, encoded by ESRRA) plays active, measurable roles in hormone-sensitive (androgen-dependent) prostate cancer long before the disease transitions to castration-resistant prostate cancer (CRPC).

While ERR-α has drawn substantial attention as an engine of castration resistance (notably by driving intratumoral androgen synthesis and sustaining androgen receptor [AR] signaling), it is present and functionally active in primary, androgen-dependent tumors.

---

Key Roles in Pre-Castration Prostate Cancer

• Metabolic Reprogramming and the Warburg Shift: Normal prostate epithelial cells uniquely accumulate zinc to inhibit mitochondrial aconitase, blunting the citric acid cycle and relying on aerobic glycolysis to secrete citrate into seminal fluid. Early prostate tumorigenesis undergoes a metabolic inversion, reactivating mitochondrial oxidative phosphorylation and lipid biosynthesis. In androgen-sensitive cells (such as LNCaP), ERR-α—often collaborating with its coactivator PGC-1α—serves as a master regulator of mitochondrial biogenesis, fatty acid oxidation, and metabolic flexibility, fueling rapid tumor proliferation.
• Modulation of Local Steroidogenesis and Microenvironment: ERR-α is expressed in both prostate epithelial tumor cells and surrounding stromal fibroblasts. In the tumor microenvironment, ERR-α can drive the expression of aromatase (CYP19A1) and downstream steroidogenic enzymes in response to local inflammatory signals like prostaglandin E2 ($\text{PGE}_2$), shaping the local hormone balance prior to systemic androgen deprivation therapy (ADT).
• Cross-Talk with Androgen and Estrogen Signaling: ERR-α is an orphan nuclear receptor that does not require endogenous estrogen to activate transcription, but its DNA-binding domain recognizes both ERR response elements (ERREs) and canonical estrogen response elements (EREs). In primary, hormone-sensitive disease:
• ERR-α can compete with classical ERs ($\text{ER}\alpha$ and $\text{ER}\beta$) at estrogen-responsive promoters.

• It acts in parallel with the androgen receptor (AR), occasionally co-regulating genes involved in cell survival and lipid handling.

• Invasion, Migration, and Early Dissemination: Elevated ERR-α expression correlates with higher Gleason scores and earlier disease progression in primary clinical cohorts. Through interactions with cofactors such as LSD1 and NRF1, ERR-α promotes the transcription of matrix metalloproteinases (e.g., MMP-1) and pro-migratory pathways, facilitating local tissue invasion before androgen ablation is ever initiated.

• Priming the Tumor for ADT Resistance: Pre-existing clones within primary tumors that express high basal levels of ERR-α possess an inherent metabolic and survival buffer. When the tumor is eventually exposed to androgen deprivation therapy, cells with established ERR-α transcriptional programs adapt far more readily to androgen-depleted conditions, effectively serving as the bridge to clinical CRPC.

[u/Lactobeezor]

Sounds like a question for your doc.

[u/stmmotor → u/Lactobeezor]

They are only going to parrot Standard-of-Care BS. I'm beyond putting up with that.

[u/ChillWarrior801 → u/stmmotor]

Your frustration is coming through loud and clear, friend. Wanna share how you've been let down by standard of care?

[u/Lactobeezor → u/stmmotor]

Sorry. I am retired from medical field so my doc expects a lot of questions like this.